fabrazyme造句

• The biotech company Genzyme Corp ., which paid for the study, is seeking government approval to market the enzyme as Fabrazyme in the United States and Europe.
• In 2009, contamination at Genzyme's Allston, Massachusetts plant caused a worldwide shortage of Fabrazyme, and supplies were rationed to patients at one-third the recommended dose.
• "But if Aldurazyme and Fabrazyme are smaller than people expect or take too long to get off the ground, that's going to be problematic for Genzyme ."
• But while Cerezyme still has no rivals, Fabrazyme faces head-to-head competition with Transkaryotic Therapies Inc ., also of Cambridge, which is developing a comparable product called Replagal.
• Genzyme has said it expects worldwide sales of Fabrazyme to reach up to $ 75 million this year, of which Tanner estimates less than $ 20 million will come from the United States.
• The FDA panel will evaluate Genzyme's application for Fabrazyme on Sept . 26 and TKT's application for Replagal on Sept . 27, and recommend whether the drugs should be approved.
• Genzyme's first-quarter selling, general, and administrative expenses grew 68 percent to $ 143.2 million, in part because of the U . S . launch of Fabrazyme.
• In June 2009, Genzyme's Allston, Massachusetts plant was shut down for production of Cerezyme, Fabrazyme, Thyrogen and Myozyme after an infection of Chinese hamster ovary cells with Vesivirus 2117.
• Robert LeBoyer, senior biotechnology analyst with Boston-based Leerink Swann & Co ., said the fact that the FDA has questions about Fabrazyme sheds little light on what will eventually happen.
• Genzyme's main objective, however, was to show that its drug, known as Fabrazyme, reduced the buildup of the GL-3 lipid in cells that line certain blood vessels in the kidneys.
• Genzyme Corp . Thursday won regulatory approval to sell its drug Fabrazyme for Fabry di1ease, beating out crosstown rival Transkaryotic Therapies Inc . to bring the first treatment for the rare genetic disorder to the US market.
• The Food and Drug Administration has completed its application review of Fabrazyme, Genzyme Corp .'s enzyme replacement drug to treat Fabry's disease, and requested additional data and another study, the company reports.
• The two companies had raced each other for approval of drugs to treat Fabry disease, but Genzyme won when its Fabrazyme was approved in April by the federal Food and Drug Administration, beating out TKT's Replagal.
• In " In the Case of Fabrazyme " patients with Fabry disease petitioned on August 2, 2010, for march-in rights in response to Genzyme's inability to manufacture enough Fabrazyme to treat all Fabry patients.
• In " In the Case of Fabrazyme " patients with Fabry disease petitioned on August 2, 2010, for march-in rights in response to Genzyme's inability to manufacture enough Fabrazyme to treat all Fabry patients.
• Genzyme, also based in Cambridge, gained the upper hand in January, when an FDA advisory panel recommended that its Fabry disease drug, Fabrazyme, be approved and that Replagal be rejected because of concerns about TKT's data.
• "Orphan drug laws dictate that only one product can get approved, and the one that will be approved is the one that is clinically superior, " said Ron Renaud, a biotech analyst at Bear Stearns who falls in the Fabrazyme camp.
• The panel endorsed a rival drug made by the Genzyme Corp ., meaning that Genzyme's drug, Fabrazyme, will probably win approval and have the market to itself for seven years under a federal law to encourage development of drugs for rare diseases.
• Supplies of Fabrazyme, Genzyme's treatment for Fabry disease, have been rationed to one-third the recommended dose prompting patients to file a petition asking for a license to produce Fabrazyme by other manufacturers to make up the deficit under the Bayh Dole Act.
• Supplies of Fabrazyme, Genzyme's treatment for Fabry disease, have been rationed to one-third the recommended dose prompting patients to file a petition asking for a license to produce Fabrazyme by other manufacturers to make up the deficit under the Bayh Dole Act.